Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy A Ross

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Urologic Oncology|November 14, 2020
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitorsJad Chahoud, Pavlos Msaouel, Jeremy A Ross, et al.
Blood|August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
Pediatric Blood & Cancer|March 13, 2026
Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 StudyDaniel A Morgenstern, Giuseppe Barone, Nadege Corradini, et al.
Blood|October 12, 2017
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myelomaShaji Kumar, Jonathan L Kaufman, Cristina Gasparetto, et al.
The Lancet. Oncology|November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
American Journal of Hematology|December 28, 2020
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myelomaJonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, et al.
International Journal of Oncology|October 2, 2012
MUC1 glycopeptide epitopes predicted by computational glycomicsWei Song, Elizabeth S Delyria, Jieqing Chen, et al.
Blood|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myelomaOla Landgren, Thomas J Prior, Tara Masterson, et al.
Pediatric Blood & Cancer|March 10, 2025
Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaAndrew E Place, Seth E Karol, Christopher J Forlenza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S Davids, Andrew W Roberts, John F Seymour, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Urologic Oncology|November 14, 2020
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitorsJad Chahoud, Pavlos Msaouel, Jeremy A Ross, et al.
Blood|August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
Pediatric Blood & Cancer|March 13, 2026
Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 StudyDaniel A Morgenstern, Giuseppe Barone, Nadege Corradini, et al.
Blood|October 12, 2017
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myelomaShaji Kumar, Jonathan L Kaufman, Cristina Gasparetto, et al.
The Lancet. Oncology|November 1, 2020
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
American Journal of Hematology|December 28, 2020
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myelomaJonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, et al.
International Journal of Oncology|October 2, 2012
MUC1 glycopeptide epitopes predicted by computational glycomicsWei Song, Elizabeth S Delyria, Jieqing Chen, et al.
Blood|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myelomaOla Landgren, Thomas J Prior, Tara Masterson, et al.
Pediatric Blood & Cancer|March 10, 2025
Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaAndrew E Place, Seth E Karol, Christopher J Forlenza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S Davids, Andrew W Roberts, John F Seymour, et al.
Pageof 8